A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 Results (n=1501) assessing the efficacy and tolerability of adjuvant antineoplastics [cisplatin + either carboplatin, docetaxel, gemcitabine, pemetrexed, or vinorelbine] with or without bevacizumab in patients with stage IB-IIIA non-small cell lung cancer, were published in the Lancet Oncology.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results of risk factors associated with brain metastases (n=121) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top